Intravitreal inj-related reactions. Not to inj while IOP is ≥30 mmHg. Withheld in patients w/ rhegmatogenous retinal detachment, stage 3 or 4 macular holes, retinal break; treatment-related decrease in best corrected visual acuity (BCVA) of ≥30 letters compared w/ last assessment of visual acuity; performed or planned intraocular surgery w/in previous or next 28 days. Patients w/ poorly controlled glaucoma; risk factors associated w/ retinal pigment epithelial (RPE) tear development after anti-VEGF therapy for nAMD include a large &/or high pigment epithelial detachment; HbA1c >10%, high-risk proliferative diabetic retinopathy; active systemic infections; diabetic patients w/ uncontrolled HTN. Arterial thromboembolic events; intraocular inflammation eg, vision loss, eye pain, increased light sensitivity, floaters, or worsening eye redness. Concomitant use of other anti-VEGF. May affect ability to drive & use machines. Women of childbearing potential should use contraception during treatment & for at least 3 mth following last dose. Not to be used during pregnancy. Lactation.
Sign Out
